Deploying wearable devices in global clinical studies offer the promise of better, more cost-efficient data for clinical trial sponsors, but what about the infrastructure behind the massive volumes of data? Unreliable cell network coverage in certain markets? Wearables’ ability to collect reliable, validated endpoint data?
Digital transformation: this is one of the hottest topics in our industry today, creating both opportunities and challenges for our customers. For pharmaceutical, biotech, and medical device companies, the promise of making data-driven, insights-led decisions in real-time means getting the right treatments to the right patients at the right time. To truly realize this potential, they need to rely on combined insights from both clinical and commercial data.
So far Edge Trial Assurance has been used in 30 trials. It has detected 50-75 data anomalies in every single trial.
Genomic data is being integrated into clinical trials—sometimes not so successfully, and sometimes very, very successfully.
The topic of Brexit tends to generate more questions than answers.